Keith Tolley1, Danny Kemmett2, Signe Thybo3, Ruth Nasr3, Helen Smethurst4. 1. Tolley Health Economics, Buxton, Derbyshire, UK. 2. Department of Dermatology, Vale of Leven Hospital, Alexandria, Dunbartonshire, UK. 3. LEO Pharma, Hurley, Berkshire, UK. 4. Abacus International, Bicester, Oxfordshire, UK. hsmethurst@dresourcesgroup.com.
Abstract
BACKGROUND: Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days). OBJECTIVE: To compare the cost-effectiveness of two strengths of ingenol mebutate gel developed to treat AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days) with other first-line AK therapies including diclofenac gel, 5-FU, 5-FU/salicylic acid, and cryotherapy for the first-line treatment of AK in adult patients, from the perspective of the National Health Service (NHS) in Scotland. METHODS: A cost-utility analysis was conducted using a decision-tree approach to calculate the costs and benefits of different treatment strategies for AK on the face and scalp or trunk and limbs over a 12-month time horizon. Data on the relative efficacy of treatments were obtained from a systematic literature review and meta-analysis. Utility scores and resource-use data were obtained from published sources. RESULTS: Over 12 months, ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were cost-effective compared with the most commonly used topical therapy in Scotland, diclofenac (3 %) gel, at a willingness-to-pay threshold of £20,000 per QALY, with a minimal additional cost of £43 and £105, respectively per QALY gained. CONCLUSIONS: Ingenol mebutate gel is a cost-effective therapy for the first-line treatment of AK from a Scottish NHS perspective.
BACKGROUND:Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days). OBJECTIVE: To compare the cost-effectiveness of two strengths of ingenol mebutate gel developed to treat AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days) with other first-line AK therapies including diclofenac gel, 5-FU, 5-FU/salicylic acid, and cryotherapy for the first-line treatment of AK in adult patients, from the perspective of the National Health Service (NHS) in Scotland. METHODS: A cost-utility analysis was conducted using a decision-tree approach to calculate the costs and benefits of different treatment strategies for AK on the face and scalp or trunk and limbs over a 12-month time horizon. Data on the relative efficacy of treatments were obtained from a systematic literature review and meta-analysis. Utility scores and resource-use data were obtained from published sources. RESULTS: Over 12 months, ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were cost-effective compared with the most commonly used topical therapy in Scotland, diclofenac (3 %) gel, at a willingness-to-pay threshold of £20,000 per QALY, with a minimal additional cost of £43 and £105, respectively per QALY gained. CONCLUSIONS:Ingenol mebutate gel is a cost-effective therapy for the first-line treatment of AK from a Scottish NHS perspective.
Entities:
Keywords:
Actinic keratosis; Cost-effectiveness; ICER; Ingenol mebutate gel
Authors: Suephy C Chen; Ahmed M Bayoumi; Seaver L Soon; Kent Aftergut; Ponciano Cruz; Shenara A Sexton; Calvin O McCall; Mary K Goldstein Journal: J Investig Dermatol Symp Proc Date: 2004-03
Authors: K S Thomas; M R Keogh-Brown; J R Chalmers; R J Fordham; R C Holland; S J Armstrong; M O Bachmann; A H Howe; S Rodgers; A J Avery; I Harvey; H C Williams Journal: Health Technol Assess Date: 2006-08 Impact factor: 4.014
Authors: Keith Tolley; Giuseppe Argenziano; Pier Giacomo Calzavara-Pinton; Thomas Larsson; Lasse Ryttig Journal: Int J Immunopathol Pharmacol Date: 2017-03-01 Impact factor: 3.219
Authors: W G Philipp-Dormston; K Müller; B Novak; K Strömer; C Termeer; U Hammann; J W Glutsch; G Krähn-Senftleben; H Lübbert; M Koller; R M Szeimies Journal: J Eur Acad Dermatol Venereol Date: 2018-01-12 Impact factor: 6.166